Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ADME, absolute bioavailability, and fraction absorbed study of PF-06700841 in healthy male volunteers
NL-OMON45995Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brepocitinib in psoriasis and inflammatory bowel disease (IBD), sponsored by Pfizer. Primary endpoint: Rate and extent of radioactivity excretion. Started Dec 2018; status: active, not recruiting.
02
Drugs
brepocitinib
03
Conditions
psoriasisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON45995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45995.